The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CELU | -42.39% | -98.25% | -55.46% | -98% |
| S&P | +12.65% | +91.73% | +13.89% | +129% |
Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.
No news articles found for Celularity.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $5.74M | -52.6% |
| Gross Profit | -$1.34M | -116.8% |
| Gross Margin | -23.36% | -89.4% |
| Market Cap | $46.94M | -31.2% |
| Market Cap / Employee | $0.38M | 0.0% |
| Employees | 123 | 2.5% |
| Net Income | -$24.52M | -278.0% |
| EBITDA | -$14.03M | -71.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.86M | 84.8% |
| Accounts Receivable | $11.15M | -17.2% |
| Inventory | 4.4 | 51.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $63.21M | 139.8% |
| Short Term Debt | $6.95M | -83.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -57.60% | 1.5% |
| Return On Invested Capital | -179.02% | -16.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.00M | 71.3% |
| Operating Free Cash Flow | -$1.00M | 71.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.41 | 2.65 | 2.20 | 5.00 | 237.71% |
| Price to Sales | 1.35 | 0.86 | 0.80 | 1.06 | -34.09% |
| Price to Tangible Book Value | 2.55 | 147.99 | 123.09 | -5.70 | -312.35% |
| Enterprise Value to EBITDA | -13.93 | -15.08 | -12.74 | -8.29 | -49.85% |
| Return on Equity | -147.5% | -232.5% | -432.3% | -6367.2% | 4028.35% |
| Total Debt | $69.06M | $68.84M | $69.78M | $70.15M | 4.16% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
